Personalis Appoints Biotech Industry Executive Clinton Musil as Chief Business Officer
Menlo Park, CA – January 3, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced the appointment of Clinton Musil as Chief Business Officer. Mr. Musil will focus initially on financing strategy. As a member of Personalis’ executive team he will also participate actively in the company’s global strategic planning, and approach to broader business relationships.
Mr. Musil joins Personalis from ARMO Biosciences, where he oversaw the Company’s $147 million initial public offering and $1.6 billion sale to Eli Lilly. Clinton has deep expertise in corporate finance and mergers and acquisitions (M&A) from the healthcare industry, including raising several billion dollars in equity and advising on more than $35 billion in M&A transactions.
“We are excited to welcome Clinton to Personalis. Clinton brings an impressive breadth of leadership within the healthcare industry, including experience working both internally and as an external advisor to support companies through key stages of growth and an array of financial transactions,” said John West, Chief Executive Officer of Personalis. “His substantial background in investment banking and associated corporate strategy will be particularly valuable as we continue to advance our high-growth commercial business and introduce our newly-launched genomics platform, ImmunoID NeXT, to our broad clientele. We look forward to Clinton’s contributions as we pursue our mission of enabling the development of next generation personalized therapeutics and diagnostics.”
Prior to joining ARMO, Mr. Musil was a Managing Director at Hercules Capital where he provided capital to life sciences companies at multiple stages of development. Clinton brings an extensive background in healthcare investment banking from several global, full service firms as well as experience as an investor at Essex Woodlands, a healthcare-dedicated fund. He holds an M.B.A. from Harvard Business School and a B.S. in Molecular and Cellular Biology from the University of Arizona.
“I am excited to join Personalis,” said Mr. Musil. “In only a few years, Personalis has established itself as a leader in advanced genomic sequencing, with a clear vision and the technical capabilities to continue developing new products that more comprehensively characterize the interactions between a patient’s cancer and immune cells to support the development of better predictive biomarkers and diagnostics. I see tremendous opportunity to build on this progress, and am excited to lend my expertise to Personalis as the partner-of-choice for biopharmaceutical companies pursing precision medicine approaches to cancer.”
About Personalis, Inc.
Personalis, Inc. is a leader in advanced genomics for precision oncology translational research and clinical trials, dedicated to enabling the development of the next generation of oncology therapeutics. The company’s ImmunoID NeXT Platform comprehensively characterizes the tumor and the tumor microenvironment, facilitating the analysis of key predictive and investigational oncology biomarkers from a single sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Investor Contact for Personalis:
Stern Investor Relations, Inc.